Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2017 (2017), Article ID 4089214, 12 pages
https://doi.org/10.1155/2017/4089214
Research Article

Neuroprotective Effect and Mechanism of Thiazolidinedione on Dopaminergic Neurons In Vivo and In Vitro in Parkinson’s Disease

1Department of Physiology, College of Life Science, Hebei Normal University, Shijiazhuang, Hebei 050024, China
2Human Movement Science, Hebei Institute of Physical Education, Shijiazhuang, Hebei 050041, China
3Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei 050051, China

Correspondence should be addressed to Zhenlong Guan

Received 29 August 2016; Revised 8 December 2016; Accepted 21 December 2016; Published 5 March 2017

Academic Editor: Maria Paola Cerù

Copyright © 2017 Yanqin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J.-H. Shin, H. S. Ko, H. Kang et al., “PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in parkinson's disease,” Cell, vol. 144, no. 5, pp. 689–702, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. T. Dextera and P. Jenner, “Parkinson disease: from pathology to molecular disease mechanisms,” Free Radical Biology & Medicine, vol. 62, pp. 132–144, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Schaeffer, A. Pilotto, and D. Berg, “Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with parkinson's disease,” CNS Drugs, vol. 28, no. 12, pp. 1155–1184, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Freitas and S. H. Fox, “Nondopaminergic treatments for Parkinson's disease: current and future prospects,” Neurodegenerative Disease Management, vol. 6, no. 3, pp. 249–268, 2016. View at Publisher · View at Google Scholar
  5. R. Fischer and O. Maier, “Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 610813, 18 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Ruszkiewicz and J. Albrecht, “Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders,” Neurochemistry International, vol. 88, pp. 66–72, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Zheng, Z. Liao, J. J. Locascio et al., “PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease,” Science Translational Medicine, vol. 2, no. 52, pp. 52–73, 2010. View at Google Scholar
  8. J. Kasahara, T. Tsukada, H. Kuroiwa et al., “Neuroprotective effect of Pioglitazone on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model for Parkinson's disease,” Journal of Pharmaceutical Sciences, vol. 118, p. 114, 2012. View at Google Scholar
  9. C. R. Swanson, V. Joers, V. Bondarenko et al., “The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys,” Journal of Neuroinflammation, vol. 8, article 91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Y. Lee, J. E. Lee, J. H. Park, I. C. Shin, and H. C. Koh, “Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats,” Toxicology Letters, vol. 213, no. 3, pp. 332–344, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. T. W. Jung, J. Y. Lee, W. S. Shim et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity,” Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 221–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Sung, S. Park, B. P. Yu, and H. Y. Chung, “Amelioration of age-related inflammation and oxidative stress by PPARγ activator: suppression of NF-κB by 2,4-thiazolidinedione,” Experimental Gerontology, vol. 41, no. 6, pp. 590–599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. K. B. Pouwels and K. Van Grootheest, “The rosiglitazone decision process at FDA and EMA. What should we learn?” International Journal of Risk and Safety in Medicine, vol. 24, no. 2, pp. 73–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Woodcock, J. M. Sharfstein, and M. Hamburg, “Regulatory action on rosiglitazone by the U.S. Food and Drug Administration,” The New England Journal of Medicine, vol. 363, no. 16, pp. 1489–1491, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. K. L. Chang, H. N. Pee, W. P. Tan et al., “Metabolic profiling of CHO-AβPP695 cells revealed mitochondrial dysfunction prior to amyloid-β pathology and potential therapeutic effects of both PPARγ and PPARα agonisms for Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 44, no. 1, pp. 215–231, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. G. A. Donnan, G. L. Willis, S. J. Kaczmarczyk, and P. Rowe, “Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse,” Journal of the Neurological Sciences, vol. 77, no. 2-3, pp. 185–191, 1987. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Haobam, K. M. Sindhu, G. Chandra, and K. P. Mohanakumar, “Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains,” Behavioural Brain Research, vol. 163, no. 2, pp. 159–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Xing, M. Liu, and G. Bing, “Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-κB and JNK activation and suppression of COX-2 activity,” Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 89–98, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Kumar, R. K. Kaundal, S. More, and S. S. Sharma, “Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease,” Behavioural Brain Research, vol. 197, no. 2, pp. 398–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Breidert, J. Callebert, M. T. Heneka, G. Landreth, J. M. Launay, and E. C. Hirsch, “Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease,” Journal of Neurochemistry, vol. 82, no. 3, pp. 615–624, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, pp. 494–501, 2008. View at Google Scholar
  22. L. P. Quinn, B. Crook, M. E. Hows et al., “The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B,” British Journal of Pharmacology, vol. 154, no. 1, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. E. Meredith and D. J. Rademacher, “MPTP mouse models of Parkinson's disease: an update,” Journal of Parkinson's Disease, vol. 1, no. 1, pp. 19–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. G. P. Selvakumar, U. Janakiraman, M. M. Essa, A. Justin Thenmozhi, and T. Manivasagam, “Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease,” Brain Research, vol. 1585, pp. 23–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Eschbach, B. Von Einem, K. Müller et al., “Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization,” Annals of Neurology, vol. 77, no. 1, pp. 15–32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Arany, H. He, J. Lin et al., “Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle,” Cell Metabolism, vol. 1, no. 4, pp. 259–271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Schilling and D. P. Kelly, “The PGC-1 cascade as a therapeutic target for heart failure,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 578–583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. D. I. James, P. A. Parone, Y. Mattenberger, and J.-C. Martinou, “hFis1, a novel component of the mammalian mitochondrial fission machinery,” Journal of Biological Chemistry, vol. 278, no. 38, pp. 36373–36379, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. C. Gomes and L. Scorrano, “High levels of Fis1, a pro-fission mitochondrial protein, trigger autophagy,” Biochimica et Biophysica Acta—Bioenergetics, vol. 1777, no. 7-8, pp. 860–866, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Cartoni, B. Léger, M. B. Hock et al., “Mitofusins 1/2 and ERRα expression are increased in human skeletal muscle after physical exercise,” Journal of Physiology, vol. 567, no. 1, pp. 349–358, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Neuspiel, R. Zunino, S. Gangaraju, P. Rippstein, and H. McBride, “Activated mitofusin 2 signals mitochondrial fusion, interferes with Bax activation, and reduces susceptibility to radical induced depolarization,” The Journal of Biological Chemistry, vol. 280, no. 26, pp. 25060–25070, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. T. W. Jung, J. Y. Lee, W. S. Shim et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production,” Journal of the Neurological Sciences, vol. 253, no. 1-2, pp. 53–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. St-Pierre, S. Drori, M. Uldry et al., “Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators,” Cell, vol. 127, no. 2, pp. 397–408, 2006. View at Publisher · View at Google Scholar · View at Scopus